Skip to main content

Peptide Profile

Epithalon

Epitalon · Epithalamin · Ala-Glu-Asp-Gly

Epithalon (Ala-Glu-Asp-Gly; AEDG peptide) is a synthetic tetrapeptide developed by Vladimir Khavinson as a more stable analog of the native pineal tetrapeptide epithalamin, proposed to restore physiological circadian rhythm…

Longevity & CellularAdvisory Vote: FavorableResearch Only
Used forlongevity
Half-life
30–60 minutes
Routes
subcutaneous, intravenous
Find providers View evidence

Educational research information — not medical advice. Review primary sources and consult a qualified professional before any decision.

Educational research tools — not medical advice.

Overview

What Epithalon is

About Epithalon

Epithalon is believed to activate telomerase, the enzyme responsible for maintaining telomere length, with several in vitro and animal studies reporting telomere elongation. It also appears to regulate the expression of p53 and other cell-cycle control genes, modulate the hypothalamic-pituitary axis via pineal gland activity, and upregulate antioxidant defences including superoxide dismutase and catalase.

Epithalon (Ala-Glu-Asp-Gly; AEDG peptide) is a synthetic tetrapeptide developed by Vladimir Khavinson as a more stable analog of the native pineal tetrapeptide epithalamin, proposed to restore physiological circadian rhythm regulation and telomerase activity in aging cells, and to exert broad anti-aging effects through epigenetic gene expression modulation in pineal and other tissues. Epithalon is proposed to activate telomerase and modulate telomere maintenance in aging somatic cells, normalize melatonin production and the neuroendocrine-immune axis, and restore physiological parameters that decline with aging; in vitro studies and preclinical animal models provide mechanistic support for these effects. Published human studies from the Khavinson group include a controlled clinical trial demonstrating epithalon's effects on retinal function in retinitis pigmentosa patients and observational data showing melatonin rhythm normalization in elderly subjects, representing the strongest indexed clinical evidence specifically for epithalon; both studies are formally indexed in PubMed. Epithalon has no FDA approval and no approved indication in any Western jurisdiction; published clinical evidence derives from a single research group without external independent replication by standard Western trial methodology, and while the mechanistic and observational research is indexed in peer-reviewed journals, the evidence base does not meet the threshold for established efficacy in any recognized clinical condition. Epithalon dosage protocols: no human clinical trial has established a standardized dosing regimen for epithalon. The published Khavinson clinical research does not report specific dose-response data in a format translatable to general dosing guidance. No dose-ranging clinical trial has been conducted for epithalon; research community protocols are derived from the animal research and Khavinson group bioregulator framework rather than validated human studies. Intranasal delivery has also been explored due to direct CNS access via the olfactory pathway. Epithalon is a research compound with no approved clinical dosing guidelines in any jurisdiction.

Epithalon Benefits & Research Areas

telomerase activation and telomere elongation in cell researchmelatonin pathway regulation via pineal gland bioregulator mechanismantioxidant and anti-aging effects (Khavinson-class tetrapeptide)subcutaneous dosing — 10–20 injection courses studied in longevity research

Research Signals

Commonly researched in the context of

Hormonal ChangesIrregular Sleep

Population research notes

40s50+

These signals reflect research interest areas, not treatment indications.

Pharmacokinetics

Epithalon half-life calculator

Compound & timing

Half-lifefrom PeptideBase data
Source: "30–60 minutes" · Epithalon (PeptideBase)
to show amount remaining
1 h
0%25%50%75%100%012.13.14.25.2time since dose (h)
Plasma decay curve for Epithalon: 25% to 50% remaining at 1 h after the dose.
range (30–60 minutes)slower half-life
25%–50%remaining in plasmaat 1 h after the dose
Half-life
30 – 60 min
~97% cleared after
5 h

Model: single-dose, first-order (single-compartment) estimate. Real clearance is multi-compartment and varies by individual and route.

The Research

What the evidence says about Epithalon

Regulatory Status

Availability Status
Research Only
FDA Status
Advisory Vote: Favorable
Effective Date
July 24, 2026
Source
View FDA source →

Synthetic tetrapeptide (Ala-Glu-Asp-Gly) from Khavinson Institute, Russia. Telomerase activator in research. No FDA approval, no NDA or IND. Not on any FDA list. Research chemical.

Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

Epithalon Side Effects & Safety Considerations

Research-use compound with limited human data. Evidence strength varies — see the Evidence section.

No established clinical contraindications. This is an investigational compound with limited human data and has not been evaluated by the FDA for safety in this context. Consult a qualified clinician.

Consult a qualified healthcare professional before making any health decisions. This information is educational only and does not constitute medical advice.

Known Interactions

1 noted
Synergistic1
GHK-Cu
Emerging

Research suggests Epithalon and GHK-Cu may produce complementary longevity-associated effects when combined. Epithalon is studied for telomere maintenance and pineal function, while GHK-Cu is studied for antioxidant gene expression and tissue remodeling — different mechanisms in aging research.

Anisimov VN et al. (2003) Effect of Epitalon on the lifespan of rats. Bull Exp Biol Med; Pickart L et al. (2015) GHK-Cu: A Peptide Regulator of Copper Transport. Cosmetics

These interactions reflect published research and are provided for educational purposes only. This is not medical advice. Consult a qualified healthcare professional before combining any compounds or medications.

Compare

VS

Epithalon

Third-party testing data

6 verified COAs

Median tested purity

99.4%

Median tested purity of 99.4% across 6 verified third-party lab COAs (interquartile range 98.8%–99.6%), as reported by the independent testing labs below. PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product.

Independent labs
Freedom Diagnostics, Janoshik Analytical
Most recent test
June 2026

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Certificates of Analysis

Cross-vendor verified23 COAs on record for Epithalon

PeptideBase reports these lab-published figures and does not itself test, endorse, or certify any product. Confirmed by lab results were matched against the issuing laboratory's own records — either the lab served the document, or its own hosted copy matches ours byte for byte. For every other result the badge states what is known about the lab: that it can be checked and no result is recorded yet, that it can't be checked, or that we have not reviewed it.

PeptideBase provides educational research tools and provider discovery. It does not provide medical advice, diagnosis, treatment, prescribing guidance, or dosing instructions. Consult a qualified healthcare professional before making health decisions.

Community Experience

What people report about Epithalon

n=37high confidence

Self-reported, anecdotal experiences aggregated from public Reddit discussions — community sentiment, not clinical evidence or medical advice.

Attribution note: many of these reports describe stacking Epithalon with other compounds, so outcomes may not be attributable to it alone.

Outcome distribution

49%improved
Improved
18 · 49%
Mixed
7 · 19%
No clear effect
9 · 24%
Worse
3 · 8%

Outcomes by goal · improved % · reports

Longevity & anti-aging41% improved · 17 reports
Sleep quality53% improved · 15 reports

Side effects people mention

Counts are mentions across reports, not incidence rates.

Vivid dreams3
Headache2
Elevated heart rate1
Fatigue1
Injection site reaction1
Mood changes1
Nausea1
Water retention1

Most reported

What they wish they'd known

Based on 37 community reports · Updated

Frequently Asked Questions — Epithalon

Epithalon (Ala-Glu-Asp-Gly; AEDG peptide) is a synthetic tetrapeptide developed by Vladimir Khavinson as a more stable analog of the native pineal tetrapeptide epithalamin, proposed to restore physiological circadian rhythm regulation and telomerase activity in aging cells, and to exert broad anti-aging effects through epigenetic gene expression modulation in pineal and other tissues. Epithalon is proposed to activate telomerase and modulate telomere maintenance in aging somatic cells, normalize melatonin production and the neuroendocrine-immune axis, and restore physiological parameters that decline with aging; in vitro studies and preclinical animal models provide mechanistic support for these effects.

telomerase activation and telomere elongation in cell research, melatonin pathway regulation via pineal gland bioregulator mechanism, antioxidant and anti-aging effects (Khavinson-class tetrapeptide), subcutaneous dosing — 10–20 injection courses studied in longevity research.

Research on Epithalon primarily documents effects related to telomerase activation and telomere elongation in cell research and melatonin pathway regulation via pineal gland bioregulator mechanism and antioxidant and anti-aging effects (Khavinson-class tetrapeptide) and subcutaneous dosing — 10–20 injection courses studied in longevity research. These are areas covered in preclinical and clinical literature — individual response varies and effects depend on context of use.

For Epithalon, its FDA status is Advisory Committee Recommended, and it is designated for research use only. Regulatory status reflects publicly available information and may change. This is not legal or medical advice.

143 providers in the directory currently offer Epithalon.

Across 51 research vendors tracked on PeptideBase, Epithalon has a median price of about $3.50 per mg, typically ranging $2.55–$4.18 per mg. This reflects research-use vendor pricing, not clinical or prescription costs.

Epithalon is featured in the following research stacks on PeptideBase: GHK-Cu + Epithalon: Anti-Aging, MK-677 + Epithalon: Sleep Architecture & Anti-Aging, Thymalin + Epithalon: Immune-Longevity Protocol.

Access

How to get Epithalon

Market Pricing

51 vendors
$2.55/mgBudget
$3.50/mgMedian
$4.18/mgPremium
$2.55
$3.50
$4.18

Price per mg varies by quantity, vendor type, and formulation. Research use only.

Data verified August 2026 · Epithalon price intelligence

Compare 51 vendors →
Compare all 51 vendors →

Where to buy Epithalon

143 providers
●104 Clinics●5 Telehealth●33 Online Vendors●1 Physician174 in stock2 on request
View all 143 providers →

Research stacks

Browse all →

Commonly stacked with

GHK-CuMK-677Thymalin

Questions to ask your provider

Stay updated on Epithalon providers

New providers added weekly — delivered to your inbox.

Weekly research digest. No spam. Unsubscribe anytime.

Last updated

Keep exploring

Tools & Guides

Reconstitution Calculator

Convert vial size + BAC water volume into draw volume.

How to Reconstitute Peptides

Step-by-step guide: BAC water, vial prep, and storage after mixing.

Peptide Dosage Guide

Key factors that determine dosing in clinical practice.

Peptide Storage Guide

How to store lyophilized and reconstituted peptides.

Cite this page

Data last updated August 26, 2026

Free to reference and republish with attribution to PeptideBase. Choose a format:

PeptideBase. (2026). Epithalon — Per-mg Price Benchmark. Retrieved September 11, 2026, from https://peptidebase.io/peptides/epithalon
https://peptidebase.io/peptides/epithalonMethodologyLicenseDownload JSONDownload CSV

Free newsletter

The Peptide Research Digest

Weekly analysis on providers, sourcing and compounds — from the team behind PeptideBase.

No spam. Unsubscribe anytime. Privacy policy.